Amicus Briefs
AdvaMed submits amicus briefs on a variety of topics because of the strong interest and relevance to the medtech industry.
Related Content
News / Amicus Briefs / Legal
AdvaMed Asks Supreme Court to Protect Innovation in False Claims Act Case
April 3, 2023
AdvaMed, the medtech association, asked the Supreme Court to affirm the judgments of the court of appeals in the Seventh Circuit in a significant case concerning the False Claims Act (FCA) Scienter Standard.
News / Amicus Briefs / Legal
AdvaMed Asks U.S. Supreme Court to Review Arbitrary and Excessive Punishments Resulting From Lack of Clarity in State Law
December 19, 2022
The Advanced Medical Technology Association (AdvaMed) asked the U.S. Supreme Court to review and reverse a California appeals court’s decision imposing over $300 million in penalties on a medical device manufacturer.
News / Amicus Briefs / Legal
AdvaMed Asks U.S. Supreme Court to Affirm Government’s Authority to Dismiss Qui Tam Suits
November 3, 2022
The Advanced Medical Technology Association (AdvaMed) has asked the U.S. Supreme Court to affirm a Third Circuit decision that confirms the government’s right to dismiss qui tam suits under the False Claims Act (FCA).
News / Amicus Briefs / Legal
AdvaMed Files Amicus Brief with California Court Opposing New Liability Theory for Products in California Courts
October 5, 2022
AdvaMed urged California’s First District Court of Appeal to overturn an erroneous decision by the trial court that has the potential to impose unfair and unwarranted liability upon companies that engage in research to move science forward.
News / Amicus Briefs / Legal
AdvaMed Files Amicus Brief with California Court of Appeal in Device Labeling Case
September 30, 2021
The Advanced Medical Technology Association (AdvaMed) issued the following statement from Pat Fogarty, Senior Vice President, Deputy General Counsel & Director of Litigation regarding this week’s filing of an amicus curiae brief in the case of People v. Johnson & Johnson:
News / Amicus Briefs / Legal
AdvaMed Applauds NJ Appellate Division for Reversing Trial Court Order Regarding FDA Evidence Admissibility
March 2, 2021
AdvaMed issued a statement regarding the decision from the New Jersey Appellate Division’s decision to remand the McGinnis case for a new trial preceded by Rule 104 hearing on the 510(k) clearance evidence.
News / Amicus Briefs / Legal
AdvaMed Participates in Oral Arguments in McGinnis v C.R. Bard
January 26, 2021
WASHINGTON, D.C. – The Advanced Medical Technology Association (AdvaMed) issued the following statement from Pat Fogarty, Vice President, Assistant General Counsel, and Director, Civil Justice Policy regarding yesterday’s oral arguments in front of the New Jersey Superior Court Appellate Division in the case of McGinnis v C.R. Bard: